Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AbbVie’s Q1 Revenue Growth Outpaces Big Pharma Peers

Apr 30 2021

• By Joseph Haas

Business report — AbbVie delivered Q1 sales growth while peers struggled with pandemic impacts

Related Content

Pfizer’s Xeljanz Could See Narrower Label And New REMS Due To CV And Malignancy Risks

Feb 11 2021

JAK-Inhibitor Review Delays Spur Talk Of US FDA Panel Meeting On Class Safety

Apr 08 2021

Keeping Track: Cloudy Horizon For Teplizumab, Roxadustat; Nuplazid Stumbles Over Subgroups; CAR-T Submissions From Gilead, J&J

Apr 10 2021

Congress Puts Focus Back On Drug Pricing With AbbVie Subpoena

Sep 02 2020

Novartis Teams Up With Sangamo In Brain Gene Therapy Pact

Jul 31 2020

AbbVie Says Botox Business Recovering But Allergan Drags Down Q2 Financials

Jul 31 2020

AbbVie Pushes Greater Flexibility With Oral Migraine Preventative Atogepant

Apr 22 2021

BI Bags Third Place For Humira Biosimilar in US With AbbVie Pact

May 16 2019

AbbVie Says “V” Is For V-Shaped Recovery

Oct 30 2020

Related Companies

AbbVie Inc.

Allergan plc

Amgen, Inc.

Novartis AG

Eli Lilly and Company

Teva Pharmaceutical Industries Ltd.

Merck & Co., Inc.

Bristol Myers Squibb Company

Pfizer Inc.

H. Lundbeck A/S

Biohaven Pharmaceutical Holding Company Ltd.

Additional Topics

Sales & Earnings Business Strategies Pricing Debate Commercial BioPharmaceutical

More from Earnings

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window